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Finally, there are suggestions in the literature that 
photoporphyrins may also be a radiosensitizer. Is it safe to 
radiate these patients after injection with DHE, and could 
this potentially provide even greater oncologic results with 
selective radiosensitization f the primary and metastatic 
tumor? 
Dr. Joseph LoCieero I I I  (Boston, Mass.). We owe a debt 
of gratitude to Dr. McCaughan for his perseverance and 
persistence with a technique that has really been an 
orphan procedure for about 15 years. This particular 
approach, the drug and the therapy, now is approved by 
the Food and Drug Administration for treatment of 
esophageal cancer. The drug is now available. The cost for 
the hospital is $2000 per vial. It remains an expensive 
therapy. Dr. Wood mentioned the cost of the laser to go 
with this. Right now it runs about $100,000. This is not a 
particularly inexpensive therapy. However, there will be a 
trial for esophageal cancer, really for dysplasia in Barrett's 
esophagus, which will begin fairly soon. The drug will also 
be presented to the Food and Drug Administration for 
approval for treatment in lung cancer and will be available 
for that therapy most likely within the year. 
I have a question specifically for Dr. McCaughan, who 
has really been a light in the darkness. Are all of these 
bronchoscopic procedures performed with the patient 
under general anesthesia and does the patient need to stay 
in the hospital? When we compare this technique with our 
present herapies, is there going to be a cost advantage to 
this particular type of therapy? 
In our early experience using PDT, which is now about 
5 years old, we found an increased incidence of problems 
with lung damage in patients who received radiation 
therapy afterward. Trying to produce an animal model or 
even a test-tube model to show that there has been 
increased sensitivity of these cells has been difficult. Do 
you have any experience to help us with that approach? 
Dr. MeCaughan. We treat these patients with x-ray 
therapy if they have not had it within a week or two after 
the treatment. We have had no increased problems from 
the radiotherapy. 
With regard to the staging, clinical staging is almost 
worthless, but it is the best thing we have. It never agrees 
with pathologic staging. It does supply all the statistics, 
which can be compared. 
The problem with doing survival curves is that these are 
elderly patients who die of other diseases. If you operated 
on 100 patients and put them in an airplane a week later 
and they all crashed and died, you would not say that your 
survival was 1 week. You have to take into account hat 
these patients have other problems, and that is what the 
standard Kaplan-Meier statistical curve does, the same as 
the actuarial curves. 
The decision was made by thoracic surgeons who 
referred the patients to us because they believed that 
these patients would not tolerate the operation because 
they already had surgery or their pulmonary functions 
were too poor. This was their decision. Because they were 
all in private practice, they were not particularly eager to 
give away patients. Most of the patients with stage I I IA 
disease had had chemotherapy and x-ray therapy. Many of 
them had had surgery. The usual litany is surgery, x-ray 
therapy, and chemotherapy. If that approach does not 
work, they are sent for PDT. Then we are asked, "Well, 
how many did you cure?" Obviously we started with 
poor-risk patients. If PDT can offer them the possibility of 
6 months' survival, it is worth trying. 
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